MLS-2384, a new 6-bromoindirubin derivative with dual JAK/Src kinase inhibitory activity, suppresses growth of diverse cancer cells

@article{Liu2014MLS2384AN,
  title={MLS-2384, a new 6-bromoindirubin derivative with dual JAK/Src kinase inhibitory activity, suppresses growth of diverse cancer cells},
  author={Lucy Q. Liu and Nicolas Gaboriaud and Konstantina Vougogianopoulou and Yan Tian and Jun Wu and Wei Wen and Leandros A. Skaltsounis and Richard Jove},
  journal={Cancer Biology \& Therapy},
  year={2014},
  volume={15},
  pages={178 - 184}
}
Janus kinase (JAK) and Src kinase are the two major tyrosine kinase families upstream of signal transducer and activator of transcription (STAT). Among the seven STAT family proteins, STAT3 is constitutively activated in many diverse cancers. Upon activation, JAK and Src kinases phosphorylate STAT3, and thereby promote cell growth and survival. MLS-2384 is a novel 6-bromoindirubin derivative with a bromo-group at the 6-position on one indole ring and a hydrophilic group at the 3′-position on… 

Oximes: Novel Therapeutics with Anticancer and Anti-Inflammatory Potential

This review is focused on oximes as kinase inhibitors with anticancer and anti-inflammatory activities.

Natural-Based Indirubins Display Potent Cytotoxicity toward Wild-Type and T315I-Resistant Leukemia Cell Lines.

Kinase assays in vitro show that eight out of the 15 active molecules strongly inhibited both c-Src and Abl oncogenic kinases in the nanomolar range, and analogue 22 is the first derivative of a natural product identified as an inhibitor of wild-type and imatinib-resistant T315I mutant Abl kinases.

The Relationship Between Janus Kinase Pathways and MicroRNAs

The relationships between JAK enzymes and miRNA are bi-directional, as the JAKs activity through JAK-STAT pathway as well as some other non-STAT pathways, control the expressions of various genes.

Strategies and Approaches of Targeting STAT3 for Cancer Treatment.

This review summarizes the development of STAT3 inhibitors organized by the approach used to inhibit STAT3, the current inhibitors of each class, and the assay systems used to evaluate STAT3 inhibition and offers an insight into future approaches for small molecule STAT3 inhibitor development.

The Multifaced Role of STAT3 in Cancer and Its Implication for Anticancer Therapy

Despite the oncogenic role of STAT3 having been widely demonstrated, an increasing amount of data indicate that STAT3 functions are multifaced and not easy to classify, which implies that the therapies based on STAT3 modulators should be performed considering the pleiotropic functions of this transcription factor and tailored to the specific tumor type.

Indirubin suppresses ovarian cancer cell viabilities through the STAT3 signaling pathway

The study provided the evidence for anti-survival activity of indirubin by inhibiting cell viability and inducing apoptosis in human ovarian cancer cells, which involved impaired STAT3 signaling pathway.

Induction of atypical cell death in thyroid carcinoma cells by the indirubin derivative 7-bromoindirubin-3′-oxime (7BIO)

The results indicate that 7BIO efficiently killed dedifferentiated thyroid carcinoma cells and induced a non-classical kind of cell death that was caspase-independent and includes DNA fragmentation.

Signal transducer and activator of transcription 3 as a therapeutic target for cancer and the tumor microenvironment

An overview of the critical roles of STAT3 in the tumor microenvironment related to cancer biology is presented and recent advancements in the development of anticancer drugs that therapeutically inhibit STAT3 signaling cascades are discussed.

STAT3 transcription factor as target for anti-cancer therapy.

Different drugs inhibiting the action of STAT3 and used in treatment of different types of cancer are summarized and discussed.

References

SHOWING 1-10 OF 50 REFERENCES

A novel 7-bromoindirubin with potent anticancer activity suppresses survival of human melanoma cells associated with inhibition of STAT3 and Akt signaling

It is demonstrated that MLS-2438, a novel natural product derivative, is a Src inhibitor and potentially regulates kinase activity of JAK2 and Akt in cancer cells, and suppressed tumor growth with low toxicity in a mouse xenograft model of human melanoma.

6-Bromoindirubin-3'-oxime inhibits JAK/STAT3 signaling and induces apoptosis of human melanoma cells.

6BIO is a novel pan-JAK inhibitor that can selectively inhibit STAT3 signaling and induces tumor cell apoptosis and support further development of 6BIO as a potential anticancer therapeutic agent that targets JAK/STAT3 signaling in tumor cells.

17-hydroxy-jolkinolide B inhibits signal transducers and activators of transcription 3 signaling by covalently cross-linking Janus kinases and induces apoptosis of human cancer cells.

17-Hydroxy-jolkinolide B (HJB), a diterpenoid from the Chinese medicinal herb Euphorbia fischeriana Steud, strongly inhibits interleukin-6-induced as well as constitutive STAT3 activation and induces apoptosis of tumor cells, particularly those tumor cells with constitutively activated STAT3.

Discovery of JSI-124 (cucurbitacin I), a selective Janus kinase/signal transducer and activator of transcription 3 signaling pathway inhibitor with potent antitumor activity against human and murine cancer cells in mice.

The suppression of phosphotyrosine STAT3 levels resulted in the inhibition of STAT3 DNA binding and STAT3-mediated but not serum response element-mediated gene transcription, giving strong support for pharmacologically targeting the JAK/STAT3 signaling pathway for anticancer drug discovery.

7-Bromoindirubin-3′-oxime induces caspase-independent cell death

Although their molecular targets remain to be identified, 7-substituted indirubins may constitute a new class of potential antitumor compounds that would retain their activity in cells refractory to apoptosis.

Triterpenoid CDDO-methyl ester inhibits the Janus-activated kinase-1 (JAK1)-->signal transducer and activator of transcription-3 (STAT3) pathway by direct inhibition of JAK1 and STAT3.

Findings indicate that CDDO-Me inhibits activation of the JAK1-->STAT3 pathway by forming adducts with both JAK2 and STAT3, and binds directly to STAT3 by a mechanism dependent on the alkylation of Cys(259).

Spirooxindole Derivative SOID-8 Induces Apoptosis Associated with Inhibition of JAK2/STAT3 Signaling in Melanoma Cells

The results indicate that the antitumor activity of SOID-8 is at least partially due to inhibition of JAK2/STAT3 signaling in melanoma cells.

Abrogation of Signal Transducer and Activator of Transcription 3 Reactivation after Src Kinase Inhibition Results in Synergistic Antitumor Effects

The reactivation of STAT3 after dasatinib treatment is caused by the engagement of a compensatory pathway that suppresses the antitumor effects of SFK inhibition and allows cancer cell survival.

Soluble 3',6-substituted indirubins with enhanced selectivity toward glycogen synthase kinase -3 alter circadian period.

The new derivatives with an extended amino side chain attached at position 3' showed potent GSK-3 inhibitory activity, enhanced selectivity, and dramatically increased water solubility, suggesting that they might constitute tools to investigate circadian rhythm regulation.

The JAK2 inhibitor AZD1480 potently blocks Stat3 signaling and oncogenesis in solid tumors.